AB Science S.A. (AB.PA)
- Previous Close
1.2360 - Open
1.3360 - Bid --
- Ask --
- Day's Range
1.2080 - 1.3400 - 52 Week Range
1.0900 - 4.9700 - Volume
107,334 - Avg. Volume
129,528 - Market Cap (intraday)
65.401M - Beta (5Y Monthly) 1.11
- PE Ratio (TTM)
-- - EPS (TTM)
-0.2000 - Earnings Date May 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
AB Science S.A., a pharmaceutical company, engages in the research, development, and marketing of protein kinase inhibitors for use in human and veterinary medicines. Its lead compound is the masitinib, a tyrosine kinase inhibitor that is in Phase III clinical trials for the treatment of prostate and pancreatic cancer, amyotrophic lateral sclerosis, multiple sclerosis, Alzheimer's, severe asthma, and mastocytosis diseases, as well as in Phase II clinical trial to treat Covid-19. The company is also developing AB8939, a synthetic microtubule destabiliser for haematology indications. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
www.ab-science.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: AB.PA
Performance Overview: AB.PA
Trailing total returns as of 6/10/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AB.PA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AB.PA
Valuation Measures
Market Cap
64.36M
Enterprise Value
77.39M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
86.90
Price/Book (mrq)
--
Enterprise Value/Revenue
79.79
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
970k
Net Income Avi to Common (ttm)
-10.05M
Diluted EPS (ttm)
-0.2000
Balance Sheet and Cash Flow
Total Cash (mrq)
--
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
--